High-dose melphalan is considered the current standard of care among the preparative regimens used in peripheral blood autologous SCT (ASCT) for multiple myeloma (MM). We report the results of a single ASCT in 79 MM patients using the BU/CY conditioning regimen, with BU 1 mg/kg p.o. or 0.8 mg/kg i.v. every 6 h Â 16 doses, and CY 60 mg/kg per day i.v. for 2 days. ASCT was carried out in first (62%) or subsequent remission/refractory disease (38%). For an overall RR of 86%, 48 and 20 patients achieved PR and CR, respectively. At a median follow-up of 41 months (range 2-132 months), the estimated median OS and PFS were 45 months (95% confidence interval (CI) ¼ 38-92) and 20 months (95% CI ¼ 15-25), respectively. The BU/CY regimen was well tolerated, and transplant-related mortality was 4%. Clinical outcomes of the BU/CY regimen are not superior to those obtained in historical controls with high-dose melphalan followed by a single ASCT. Therefore, considering even the greater complexity of administration of the BU/CY regimen compared with that of single-agent melphalan, we believe the latter should remain the conditioning regimen of choice for ASCT in MM.
Introduction
Several randomized and nonrandomized trials have demonstrated the superiority of high-dose chemotherapy followed by autologous SCT (ASCT), either single or in tandem, in prolonging overall and disease-free survival in patients with multiple myeloma (MM) compared to conventional chemotherapy. [1] [2] [3] Many transplant centers consider single-agent melphalan at the dose of 140-200 mg/m 2 the current standard of care among several conditioning regimens used for ASCT in MM patients. 4 Single-agent melphalan has replaced previous regimens that incorporated TBI, because of similar survival and reduced toxic death rate when compared with TBI-containing protocols. 5 Between 1998 and 2006, our transplant program used a combination of BU and CY (BU/CY) as the preparative regimen for myeloablative ASCT in patients with hematological malignancies. The BU/CY combination was developed as an alternative to TBI-based conditioning regimens, and it was commonly used in patients with myeloid leukemias. 6 The expected effectiveness of BU and CY in MM was attributed to the fact that both drugs-like melphalan-belong to the class of alkylating agents and are cycle nonspecific: alkylating agents exert their cytotoxic effect in both dividing and quiescent (G 0 ) cells, an important aspect when considering that the entire MM mass issues from a small proportion of proliferating cells, and actively cycling cells often constitute o4% of malignant plasma cells. 7 In this study, we report a single institution's experience with 79 consecutive MM patients treated with the BU/CY regimen followed by a single ASCT without maintenance therapy.
Patients and methods
After obtaining permission from our institutional review board, we performed a systematic retrospective review of all medical charts and BM transplant database of MM patients treated at Penn State Milton S Hershey Cancer Institute between 1998 and 2006. We identified 79 consecutive MM patients who underwent ASCT after conditioning with BU and CY.
PBSCs were mobilized with combination chemotherapy, which consisted of CY 5000 mg/m 2 þ etoposide 1000 mg/m 2 i.v., followed by G-CSF 5 mg/kg per day until the end of stem cell collection. Autologous stem cells were infused on day 0, and G-CSF 5 mg/kg per day was given from day þ 1 until neutrophil engraftment. Phenytoin was administered for seizure prophylaxis, and antiemetic therapy and antimicrobial prophylaxis were administered according to standard institutional guidelines. Neutrophil engraftment was defined as an ANC 40.5 Â 10 9 per liter, and platelet engraftment as a platelet count 420 Â 10 9 per liter without transfusion support. Irradiated blood products were administered during pancytopenia to maintain Hb 48 g/100 ml and platelets 410 000 per ml.
No maintenance therapy was given. Disease status and responses were assessed both before ASCT (after mobilization chemotherapy) and 2-3 months after ASCT, according to previously accepted guidelines. 8 OS and PFS were measured from the day of transplant (day 0). Statistical analysis was performed using the software program SAS System, version 9.1. OS and PFS curves were plotted using the Kaplan-Meier method. ) of IBW was mobilized and subsequently infused at the time of the transplant. Patients achieved neutrophil engraftment at a median of þ 13 days (range þ 6 to þ 21 days), and platelet engraftment at a median of 14 days (range þ 11 to þ 24). Patients required a median of 2 units of RBC transfusions (range 0-8), and 6 units of platelets transfusion (range 0-90).
Results

Patient characteristics and ASCT
After transplant, 9 of 56 patients in PR achieved CR, and 4 of 12 patients with refractory disease achieved PR (no CR), therefore 13 of 68 patients (19%) had an improvement of their disease status after the ASCT.
Toxicities
The BU/CY regimen was well tolerated. None of the patients developed seizures with phenytoin prophylaxis, and no case of clinically significant hemorrhagic cystitis was observed. BU-related pulmonary toxicity developed in two patients, and one of them died on day þ 57. Veno-occlusive disease (VOD) of the liver occurred in four patients, and was reversible in three cases, whereas one patient died on day þ 68. Twenty-eight patients (36%) experienced neutropenic fever. Twenty-three patients (29%) developed significant oral mucositis, requiring total parenteral nutrition and/or patient-controlled analgesia with i.v. opioids. No therapy-induced myelodysplastic syndrome or acute leukemia was seen. Transplant-related mortality was 4%, with three patients dying of VOD, pneumonia and BUrelated pulmonary toxicity. No significant differences in type and incidence of toxicities were observed between the groups of patients receiving p.o. vs i.v. BU (data not shown).
Survival analysis
Response rate in the overall cohort of patients was 86%: 48 patients with PR, 20 with CR and 11 with no response/PD. After a median follow-up of 41 months (range 2-132 months), 32 of 79 patients (41%) died, 28 of them due to progressive MM. Twenty-seven patients (34%) experienced disease progression or relapse, and twenty (25%) were in remission, either PR or CR. The Kaplan-Meier estimate of median OS from the time of transplant was 45 months (95% confidence interval (CI) ¼ 38-92; Figure 1 ). Median PFS was 20 months (95% CI ¼ 15-25; Figure 2 ). The 5-year OS and PFS were 46 (95% CI ¼ 31-62) and 26% (95% CI ¼ 13-40), respectively.
Median PFSs with p.o. (n ¼ 13) vs i.v. (n ¼ 66) BU were 20 and 15 months, respectively, a difference statistically nonsignificant (P40.05; Figure 3 ). Difference in median OS was not statistically significant (data not shown).
Median OS between the group of patient receiving an ASCT 'upfront', that is, in first remission (n ¼ 62) and that one receiving an ASCT as 'salvage therapy', that is, on disease progression/relapse (n ¼ 17) was not statistically significant (P40.05), either calculating OS from the day of ASCT (data not shown), or from the time of diagnosis ( Figure 4 ).
Discussion
Many transplant centers consider single-agent melphalan the current standard of care among various conditioning regimens used for ASCT in MM. Our study summarizes our institution's experience with a regimen consisting of two different alkylating drugs, BU and CY. The relevance of our findings is limited by the retrospective nature of the study and by the heterogeneity of our patient population, because it included newly diagnosed MM patients in first remission, and patients in whom ASCT was used as salvage therapy, that is, in case of disease relapse or progression. On the other hand, our patients are representative of a 'real-world' population of MM patients referred to a transplant center from oncologists in the community. Our findings suggest that the BU/CY regimen, followed by a single ASCT and without maintenance therapy, has significant activity in MM, but it did not provide outcomes superior to those achieved in a similar setting with highdose melphalan: in fact, a large study of 451 newly diagnosed MM patients treated with melphalan 200 mg/m 2 followed by a single ASCT has shown an OS and event-free survival (EFS) of 5.9 and 2.4 years, respectively. 9 Mortality of ASCT in this study was 6%, similar to that which we observed with the BU/CY regimen. Other studies of single ASCT in MM have shown a median OS of 48-69 months. 3, [10] [11] [12] [13] [14] [15] [16] Few studies have published the use of the BU/CY regimen in MM patients, [17] [18] [19] but no sufficient data are available regarding clinical outcomes associated with the i.v. administration of BU compared with the oral formulation in the setting of ASCT for MM. The i.v. formulation should provide more predictable pharmacokinetics, but in our study, it did not show an advantage over the oral one, in terms of either EFS or OS. Another interesting aspect of our data is the lack of survival advantage of ASCT carried out at relapse when compared with the 'upfront' use of ASCT, that is, when carried out at first remission of disease. Obviously, the implication of our data is very limited, because this is a retrospective analysis and the number of patients treated with 'salvage' transplant was small.
The use of the BU/CY regimen in MM has been reported by another group, which found an OS and PFS of 57 and 26 months, respectively. 16 The higher median OS and EFS in that study is possibly related to the fact that 36% of those patients received maintenance therapy, with either IFN-a, thalidomide or alternate-day prednisone. As a conditioning regimen for ASCT in MM, high-dose melphalan has remained the agent of choice, despite several attempts to use other alkylating agents in various combinations. For example, a recent study comparing outcomes of ASCT in 48 patients treated with melphalan vs those in 62 patients treated with BU, CY and etoposide (BCV regimen) has shown equivalent OS, EFS and toxicities. 20 Another study with BCV in 28 MM patients showed OS and PFS of 43 and 24 months, respectively. 21 Other trials investigating a more intensive regimen of thiotepa, BU and CY described results similar to those achieved with single-agent melphalan. 22, 23 A study of 472 MM patients compared four different transplant regimens: melphalan 200 mg/m 2 (Mel200), melphalan 140 mg/m 2 þ TBI (Mel-TBI), BU-melphalan (BuMel) and BU-CY (BUCY). Despite a better response rate observed in the BuMel group, and better OS of the BuMel vs the BUCY group (57 vs 39 months, respectively), differences in outcomes were not conclusive, and the BUCY group was small, including only 28 patients. 24 Dose intensification of conditioning regimen can be potentially dangerous: a study in 56 MM patients added idarubicin and CY to melphalan 200 mg/m 2 , but this was followed by a treatment-related mortality of 20% (vs 0% in the standard arm with melphalan 200 mg/m 2 ), which lead to early discontinuation of the study. 25 Another investigational strategy has been to increase the dose of single-agent melphalan to 4200 mg/m 2 with the concurrent use of the cytoprotective agent amifostine, 26, 27 but data are too preliminary to justify the use of this approach in routine clinical practice.
Toxicity of the BU/CY regimen is acceptable. Of 79 patients, 4 developed VOD, an expected complication of the BU/CY regimen. 28 The incidence of hepatic VOD found in our study is similar to the 8% reported in a large trial combining BU with melphalan in MM patients undergoing ASCT. 29 Because the administration of melphalan consists of a single i.v. infusion over 15-20 min, it is much simpler and more convenient than our BU/CY regimen or other combinations requiring multiple infusions administered over several days. Single-agent melphalan requires a shorter hospitalization, and it actually can be administered on an outpatient basis. Thus, in view of its simpler schedule of administration and lack of superior outcomes, we conclude that i.v. melphalan should remain the agent of choice for conditioning of ASCT in MM, to which all other regimens should be compared.
Recent publications of high-dose chemotherapy and ASCT in MM patients have shown outcomes significantly superior to those seen with single-agent melphalan or our BU/CY regimen: these approaches have involved a more aggressive strategy, incorporating the use of relatively novel agents such as bortezomib and thalidomide in the upfront induction therapy, tandem transplants, post transplant consolidation chemotherapy, and maintenance therapy. 30, 31 Of note, those results are superior even due to factors not inherent with the therapeutic approach, but depending on patient selection, such as the inclusion of patients with good performance status and newly diagnosed disease, with exclusion of those with MM at relapse or progression.
In conclusion, we report our single-institution experience of the BU/CY preparative regimen before ASCT for patients with MM. On the basis of current knowledge, it is clear that further advances in the treatment of MM, and the ultimate goal of cure, cannot be reached by 'tweaking' or intensifying chemotherapy regimens in preparation of transplant, but it can only occur with the integration of novel biological agents with activity directed against the pathogenetic mechanisms of transformation of malignant plasma cells.
